explore -WSS

explore

author：explore 2025-10-01 20:15:31 - browse：3785

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： ACIP vaccine advisory panel sees its vacancies filled

Wikipedia

explore

WSS

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Study gives hint on South Asians’ higher risk of cardiovascular disease

Study gives hint on South Asians’ higher risk of cardiovascular disease

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Second House panel advances two

Having children helps parents live longer, especially after age 80

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Malaria cases in Florida and Texas: Here’s what you need to know

Solving academic medical centers' existential crisis

Jerome Adams on the need for new antivirals for Covid

Criminal prosecution for violating HIPAA: an emerging threat

How to save PrEP access — and even expand it

Wearables generate powerful data but its not useful to doctors, yet

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

hotspot

Readers respond to H5N1 and livestock movements, and more

Military medical care influenced by rank and race, new study finds

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

AMAs digital advisors table RPM coding reform proposal, again

Wearables generate powerful data but its not useful to doctors, yet

Wikipedia

explore

hotspot

knowledge